$CATL(03750)$ gained from expanding overseas battery orders and accelerating energy storage—booked a small profit. My first trade qualified for Contra 688, and the SGD688 voucher arrived instantly. With a deep tech moat, any pullback is a buying opportunity.
$Broadcom(AVGO)$ The demand for AI chips, especially in networking, remains vastly underestimated. As a key enabler, Broadcom's revenue potential isn't fully priced in yet. I firmly believe in my thesis – its growth trajectory will smash expectations in the coming years. Still bullish!
Wolfspeed $Wolfspeed Inc.(WOLF)$ ’s shares closed at $31.10, down sharply after a recent sell-off. Despite this drop, the stock is still up over 40% year-to-date, showing how volatile trading has been.Earlier this year, Wolfspeed’s stock surged more than 1,100% when a court approved its bankruptcy reorganization plan, marking a dramatic turnaround from financial distress. However, the company also needed to complete a reverse split to maintain its public listing, signaling that challenges remain.Investors are now reassessing whether the latest weakness signals a buying opportunity or a sign of deeper challenges.Valuation Looks LowWolfspeed is currently trading at a price-to-sales ratio of 1.1x, well below the peer average of 3.1x and the U.S. semi
$IREN Ltd(IREN)$ If you bought when it was cheap- I am super happy for you. I have written about this stock since 2024 when it was at $6.But buying up here is not only dangerous but irresponsible.Big difference in buying a company you like on a dip VS buying it when everything is HOT as an Oven.
$SoundHound AI Inc(SOUN)$ This main force is aggressive—pre-market already testing the $15.5 resistance! Since buying SOUN, every morning brings a pleasant surprise. It’s safe to say: SOUN is back!
$VanEck Semiconductor ETF(SMH)$ trade secured a small profit with disciplined entry. Chip sector recovery and AI demand drove gains—staying patient amid volatility. Will scale out gradually to lock in tech rebound gains.
$Direxion Daily S&P Biotech Bull 3x Shares(LABU)$ 's performance is truly impressive! As a 3x leveraged biotech ETF, it perfectly captured the dual catalysts of accelerated drug approvals and breakthroughs in gene therapy - when this sector moves, it really takes off. Of course, with leveraged products' volatility, my strategy remains disciplined position sizing + long-term tracking. Steady and strategic!